Boston Scientific Corporation (BSX) vs Regeneron Pharmaceuticals, Inc. (REGN)
A side-by-side comparison of Boston Scientific Corporation and Regeneron Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of July 31, 2026. Differences are shown without an overall score or investment verdict.
BSX
Boston Scientific Corporation
$46.73HealthcareDelayed quote: Jul 31, 2026, 4:00 PM EDT
REGN
Regeneron Pharmaceuticals, Inc.
$762.63HealthcareDelayed quote: Jul 31, 2026, 4:00 PM EDT
Total return — BSX vs REGN
growth of $100 · dividends reinvested · last 30yBSX +318.9%REGN +4818.8%REGN compounded faster
Log scale — wide-divergence pair
BSX REGN
BSX vs REGN: by the numbers
- •REGN is the larger company ($78.57B vs $69.46B market cap).
- •REGN trades at the lower trailing earnings multiple (18.86 vs 19.00 P/E), one valuation lens rather than an overall verdict.
- •REGN converts more revenue to profit (27.86% vs 17.48% net margin).
- •BSX grew revenue faster over the past five years (13.40% vs 4.64% CAGR).
- •REGN pays a dividend (0.48% yield), while BSX has no payments in the available dividend history.
Metrics side by side
Valuation
| Metric | BSX | REGN |
|---|---|---|
| P/E ratio | 19.00 | 18.86 |
| Forward P/E | 14.11 | 14.62 |
| P/S ratio | 3.30 | 5.24 |
| P/B ratio | 2.70 | 2.10 |
| PEG ratio | 0.88 | 3.38 |
| EV / EBITDA | 14.14 | 19.81 |
| FCF yield | 4.93% | 4.62% |
Profitability
| Metric | BSX | REGN |
|---|---|---|
| Gross margin | 71.16% | 88.11% |
| Operating margin | 21.60% | 24.74% |
| Net margin | 17.48% | 27.86% |
| ROE | 14.19% | 11.15% |
| ROIC | 8.78% | 8.51% |
Dividends
| Metric | BSX | REGN |
|---|---|---|
| Dividend yield | N/A | 0.48% |
| Payout ratio | N/A | 8.45% |
Growth (annualized)
| Metric | BSX | REGN |
|---|---|---|
| Revenue CAGR (5Y) | 13.40% | 4.64% |
| EPS CAGR (5Y) | N/A | 5.70% |
| FCF CAGR (5Y) | 19.89% | 17.30% |
| Total return CAGR (5Y) | 0.49% | 5.99% |
Frequently asked
- Which has the lower trailing P/E, BSX or REGN?
- REGN has the lower trailing P/E: BSX trades at 19.00 and REGN at 18.86. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, BSX or REGN?
- Over the past five years, BSX grew revenue faster — BSX at a 13.40% CAGR versus REGN at 4.64%.
- Does BSX or REGN pay a bigger dividend?
- REGN pays a dividend (0.48% yield), while BSX has no payments in the available dividend history.
- Is BSX or REGN more profitable?
- REGN runs the higher net margin — BSX at 17.48% versus REGN at 27.86%.
- How have BSX and REGN total returns compared?
- Over the past 10 years, BSX delivered 6.76% and REGN delivered 6.10% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Boston Scientific P/E ratioRegeneron Pharmaceuticals P/E ratioBoston Scientific dividend yieldRegeneron Pharmaceuticals dividend yieldBoston Scientific ROERegeneron Pharmaceuticals ROEBoston Scientific operating marginRegeneron Pharmaceuticals operating marginBoston Scientific revenue growthRegeneron Pharmaceuticals revenue growthBoston Scientific free cash flowRegeneron Pharmaceuticals free cash flow
Boston Scientific & Regeneron Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified July 31, 2026.